Intra-Cellular Therapies, Inc.
ITCI
Rangering i aksjer
#1674
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aksjekurs
$131.87
Sist synkronisert: 2025-04-02
Markedsverdi
$12.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Aksjeprishistorikk for Intra-Cellular Therapies, Inc. (ITCI)
Høyeste sluttskurs: $131.87 den 2025-04-01
Laveste sluttskurs: $18.58 den 2014-01-01
Laveste sluttskurs: $18.58 den 2014-01-01
Aksjeprishistorikk for Intra-Cellular Therapies, Inc. fra 2014 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2025 | 55.77% |
| 2024 | 28.97% |
| 2023 | 25.44% |
| 2022 | 22.29% |
| 2021 | 54.57% |
| 2020 | 49.37% |
| 2019 | 44.08% |
| 2018 | -15.24% |
| 2017 | -2.14% |
| 2016 | -71.45% |
| 2015 | 222.13% |
| 2014 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.88 | 21.06% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $223.59 | 30.57% |
CH
|
|
| $18.43 | -4.03% |
IN
|
